This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. Eli Lilly (NYSE:LLY) has quickly emerged as one of Wall ...

Eli Lilly stock is down 13% from its 52-week high. Analysts still see some decent upside for the stock, with its average price target being north of $1,200. The company experienced tremendous growth ...

Eli Lilly's GLP-1 drug portfolio should power the business for at least the next decade. But the market appears well aware of the company's weight loss drug success. Weight loss drugs are set to ...

Eli Lilly said it is lowering the cash prices of single-dose vials of its blockbuster weight loss drug Zepbound on its direct-to-consumer platform, LillyDirect. Starting Dec. 1, cash-paying patients ...

Forbes contributors publish independent expert analyses and insights. Peter Cohan, a Boston-based senior contributor, covers stocks. Eli Lilly achieved a $1 trillion market cap, a healthcare first, ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Lilly is looking to build four ...

Eli Lilly said its next-generation obesity drug delivered what appears to be the highest weight loss seen so far in a late-stage trial and reduced knee arthritis pain, clearing the first of several ...

Eli Lilly's success rate in clinical trials was phenomenal last year. The drugmaker has made a big name for itself in diabetes and weight loss. But it's also proving innovative even beyond its core ...

Global pharmaceutical firm Eli Lilly and Co. will invest $3.5 billion to build a manufacturing plant in Upper Macungie Township that is expected to create 850 jobs. “This is the largest single project ...